Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 38.1% during trading on Thursday . The stock traded as high as C$0.15 and last traded at C$0.15. 605,625 shares changed hands during trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Trading Up 20.0 %
The firm has a 50 day simple moving average of C$0.09 and a 200 day simple moving average of C$0.07. The firm has a market capitalization of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Stock Sentiment Analysis: How it Works
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Read Stock Charts for Beginners
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
